BIOCON LTD.

Biocon Limited has secured market entry for its proposed biosimilar to Stelara®, Yesintek™ (Ustekinumab), in nine additional global markets including Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This agreement with Janssen Sciences Ireland builds upon previous agreements for the US, Europe, UK, Canada, and Japan. Yesintek™ is an interleukin-12 and -23 antagonist approved for treating autoimmune diseases like Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The reference drug, Stelara®, had worldwide sales of $6.08 billion in 2025. This expansion aims to provide affordable treatment options for patients in these new markets, subject to regulatory approvals.

Biocon Limited has reached a global settlement and license agreement with Genentech, resolving patent disputes and securing early licensed launch dates for its biosimilar, Pebrilzo® (bPertuzumab). This agreement allows Biocon to launch Pebrilzo® in the European Union and UK in Q1 CY2027, in the U.S. in Q3 CY2028, and in other Rest of the World countries between CY2026-2028, subject to regulatory approvals. Pebrilzo® is a biosimilar to Perjeta® (Pertuzumab) and is used for treating HER2-positive breast cancer.

Biocon Ltd has received an Order-In-Original from the Assistant Commissioner (ST) in Visakhapatnam, Andhra Pradesh. The order confirms a Goods and Service Tax demand of ₹1,85,28,762/-, interest of ₹1,17,59,033/-, and a penalty of ₹18,52,476/- for the Financial Year 2022-23. The issues cited include non-submission of SEZ endorsement documents, incorrect input tax reversal, and improper claim of Input Service Distribution credits. Biocon states there is no material financial impact and intends to file a Rectification Application or Appeal. The total demand, including penalty and interest, amounts to approximately ₹3.04 Crore.

Biocon Ltd has announced the grant of 94,60,232 stock options to eligible employees under its "Growth Accelerator" Plan 2026 and related schemes. The effective grant date is October 01, 2026, with an exercise price of ₹5 per option. No options have vested as of the grant date, and vesting will occur according to the grant letter's schedule. Options can be exercised within 12 months of vesting. The plans comply with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The Nomination and Remuneration Committee administers the plans, which will be implemented through the Biocon India Limited Employees Welfare Trust.

Biocon Limited has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from Thursday, October 01, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter and half-year ending September 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Biocon Limited announced that its Malaysian subsidiary has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill finish unit for Semglee® (insulin glargine). This follows a similar approval from the European Medicines Agency (EMA) in July. The facility is located at Biocon's insulin manufacturing site in Malaysia. This development is significant for Biocon's biosimilar insulin production and market expansion in regulated markets.

Biocon Biologics Limited announced that its Pertuzumab biosimilar, Pebrilzo®, has received a positive opinion from the EMA's CHMP for marketing authorisation. This marks the first biosimilar to achieve this under EMA's tailored clinical development approach. The recommendation is for the treatment of HER2-positive breast cancer across multiple stages. The European Commission will now conduct the final review. The product's analytical and clinical pharmacology data demonstrated high similarity to the reference biologic with no clinically meaningful differences in quality, safety, or efficacy.

Biocon Ltd has announced the remittance of its final dividend for the financial year 2025-26. The dividend of ₹0.50 per equity share of face value ₹5/- was approved by the company's members at the 48th Annual General Meeting held on August 06, 2026. The dividend has been remitted through electronic mode to shareholders who have registered their email IDs or addresses with the Registrar & Share Transfer Agent. Shareholders are advised to verify the credit in their bank accounts and contact KFin Technologies Limited, the RTA, in case of any discrepancies.

Biocon Limited has announced a significant 10-year supply contract for Pertuzumab in Brazil, a HER2-positive breast cancer therapy. This agreement, part of Brazil's Productive Development Partnership (PDP) program, is a collaboration with Bahiafarma and Bionovis. The consortium secured 100% allocation in the PDP, granting exclusive access to Brazil's public healthcare market, which represents approximately 70% of the country's demand for Pertuzumab. Biocon will benefit from milestone payments and a share of revenues over the contract period. The partnership also includes phased localization of the product in Brazil, aiming to enhance local manufacturing capabilities and expand access to this critical cancer treatment within the Unified Health System (SUS).

Biocon Ltd has announced the remittance of its final dividend for the financial year 2025-26. The dividend, approved at the 48th Annual General Meeting held on August 6, 2026, amounts to ₹0.50 per equity share (face value ₹5). Shareholders whose email addresses are registered with the RTA or Depository Participants have received the dividend electronically. The company has also informed shareholders to verify the credit in their bank accounts and to contact KFin Technologies Limited, the Registrar & Share Transfer Agent, in case of any discrepancies.